(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






1712 Result: Health

Diplomat to Dispense DUPIXENT(R) to Treat Atopic Dermatitis

March 28th, 2017

The nation’s largest independent specialty pharmacy will dispense DUPIXENT® (dupilumab) to treat adults who have moderate-to-severe atopic dermatitis. FLINT, Mich. / CRWE PRESS RELEASE / March 28, 2017 – Diplomat Pharmacy, Inc. (NY. Read more

FDA approves drug to treat Parkinson's disease

March 21st, 2017

Silver Spring, MD / CRWE PRESS RELEASE / March 21, 2017 - The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa . Read more

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases

March 20th, 2017

* Builds upon initial 2014 alliance in oncology * Includes up to eight additional targets in oncology and other therapeutic areas * CytomX to receive $200 million upfront payment NEW YORK and SOUTH SAN FRANCISCO / CRWE PRESS RELEASE / March 20, . Read more

Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million

March 16th, 2017

Caladrius expected to emerge as a well-capitalized cell therapeutics-only development company with multiple proprietary technology platforms Conference call begins tomorrow, March 17, 2017 at 8:30 am Eastern time BASKING RIDGE, N.J. / CRWE PRES. Read more

ERF Wireless, Inc. Announces Major Changes to Board of Directors

March 16th, 2017

LEAGUE CITY, Texas / CRWE PRESS RELEASE / March 13, 2017 - ERF WIRELESS, INC. ("ERF") (OTC PINK: ERFB) today announced major changes to its board of directors. Three (3) new directors including Steven M. Sarno, Dr. John B. Barnett, and Joey Milan wer. Read more

Kitov Announces License Agreement for KIT-302 in South Korea

March 08th, 2017

Definitive agreement grants Kuhnil Pharmaceutical Co. Ltd. an exclusive license to manufacture and market KIT-302 in South Korea Transaction is Kitov's First License Agreement for KIT-302 Celecoxib is the leading NSAID product in South Kore. Read more

Aquentium Announces Plans to Manufacture Mineral Spring Bottled Water Infused with Cannabidiol "CBD"

March 08th, 2017

Canyon Lake, CA / March 08, 2017 - Aquentium, Inc. (OTC:AQNM) announced today that its board of directors recently approved the formation of a wholly owned subsidiary for the manufacturing of mineral spring bottled water infused with cannabidiol &ldq. Read more

ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1(R) Access to Over 12 Million Beneficiaries

March 06th, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 6, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced it has attained out-of-state provider status with Medi-Cal, California’s Medicaid program, for OVA1®/Multivari. Read more

ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1(R)

March 01st, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 1, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contracted agreement with Blue Cross Blue Shield of Michigan for ASPiRA’s U.S. FDA cleared, American Colle. Read more

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

February 13th, 2017

HAIFA, Israel / CRWE PRESS RELEASE / February 13, 2017 - Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for . Read more

Kitov Provides Further Update on Formal Investigation by Israeli Securities Authority

February 09th, 2017

Tel Aviv, Israel / CRWE PRESS RELEASE / February 9, 2017 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, in response to requests made by the NASDAQ Stock Market, today provided a further upda. Read more

Walgreens Boots Alliance and Rite Aid Enter into Amendment and Extension to Merger Agreement

January 30th, 2017

Deerfield, Ill. and Camp Hill, Pa. / CRWE PRESS RELEASE / January 30, 2017 - Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Rite Aid Corporation (NYSE: RAD) today announced that they have entered into an amendment and extension of their previously . Read more

Inovalon Announces Agreement with Boehringer Ingelheim to Support Outcome-Based Contracting

January 23rd, 2017

Inovalon platform to empower expanded insight and improvement in outcomes for value-based medication offerings Bowie, Md. / CRWE PRESS RELEASE / January 23, 2017 – Inovalon (Nasdaq: INOV), a leading technology company providing advanced, clo. Read more

Qualcomm Comments on Apple Complaint

January 22nd, 2017

SAN DIEGO / CRWE PRESS RELEASE / Jan. 20, 2017 - “While we are still in the process of reviewing the complaint in detail, it is quite clear that Apple’s claims are baseless. Apple has intentionally mischaracterized our agreements and nego. Read more

Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

January 17th, 2017

* PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients * This approval joins those from the U.S. FDA and U.K. fo. Read more

Load More Content